Deoxycytidine in human plasma: Potential for protecting leukemic cells during chemotherapy

Cancer Letters

Volumn 116, Issue 2, 1997, Pages 167-175

  Cohen, Justin D ^a   Strock, David J ^a   Teik, Joanne E ^a   Katz, Torrey B ^a   Marcel, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

2 chlorodeoxyadenosine; Cytosine arabinoside; Deoxycytidine; Fludarabine; Human; Leukemia

Indexed keywords

CLADRIBINE; CYTARABINE; DEOXYCYTIDINE; DEOXYCYTIDINE TRIPHOSPHATE; DNA; FLUDARABINE;

ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CASE REPORT; CELL PROTECTION; CELL STRAIN HL 60; CONTROLLED STUDY; DNA DEGRADATION; DNA SYNTHESIS; DRUG METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA CELL; PRIORITY JOURNAL;

ADULT; CLADRIBINE; CYTARABINE; DEOXYCYTIDINE; DEOXYCYTOSINE NUCLEOTIDES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; VIDARABINE;

EID: 0030873288     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00185-7     Document Type: Article

References (30)

1. Chan T.S. Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity. Proc. Natl. Acad. Sci. USA. 76:1979;925-929.
2. Chasty R.C., Liu-Yin J.A. Acute tumor lysis syndrome. Br. J. Hosp. Med. 49:1993;488-492.
3. Rustum Y.M., Raymakers R.A.P. 1-β-D-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmac. Ther. 56:1992;307-321.
4. Griffig J., Koob R., Blakley R.L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 49:1989;6923-6928.
5. Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Semin. Oncol. 17:1990;3-17.
6. Jamieson G.P., Snook M.B., Wiley J.S. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leukemia Res. 14:1990;475-479.
7. Hajek A.S., Parrish R.K., Mallick K.S., Gressel M. In vitro inhibition of ocular cell proliferation with araC: blockage of the antiproliferative effect with 2′-deoxycytidine. Invest. Ophthalmol. Visual Sci. 27:1986;1010-1012.
8. Martin D.P., Wallace T.L., Johnson E.M. Jr. Cytosine arabinoside kills post-mitotic neurons in a fashion resembling trophic factor deprivation. J. Neurosci. 10:1990;184-193.
9. Bhalla K., MacLaughlin W., Cole J., Arlin Z., Baker M., Graham G., Grant S. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitors from cytosine arabinoside-mediated cytotoxicity. Blood. 70:1987;568-571.
10. Vilpo J.A. Effect of cytosine arabinoside on the human immunosystem: toxicity against quiescent human peripheral blood mononuclear cells in vitro. Int. J. Immunopharm. 9:1987;379-383.
11. Danhauser L.L., Rustum Y.M. Effect of thymidine on the toxicity, antitumor activity, and metabolism of 1-β-D-arabinofuranosylcytosine in rats bearing a chemically induced colon carcinoma. Cancer Res. 40:1980;1274-1280.
12. Chiuten D.F., Wiernik P.H., Zaharko D.S., Edwards L. Clinical phase I-II and pharmacokinetic study of high dose thymidine given by continuous infusion. Cancer Res. 40:1980;818-822.
13. Harris A.L., Grahame-Smith D.G. Cytosine arabinoside triphosphate production in human leukemic myeloblasts: interactions with deoxycytidine. Cancer Chemother. Pharmacol. 5:1981;185-192.
14. Ohno Y., Spriggs D., Matsukage A., Ohno T., Kufe D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β Cancer Res. 48:1988;1494-1498.
15. Young I., Young G.J., Wiley J.S., van der Weyden M.B. Nucleoside transport and cytosine arabinoside (araC) metabolism in human T lymphoblasts resistant to araC, thymidine and 6-methylmercaptopurine riboside. Eur. J. Cancer Clin. Oncol. 21:1985;1077-1082.
16. Liliemark J.O., Plunkett W. Regulation of 1-β-D-arabinofuranosylcytosine-5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res. 46:1986;1079-1083.
17. Cohen J.D., Robins H.I., Katz T.B., Miller E.M., Kuzminsky S.R., Javid M.J. Deoxyribonucleotide triphosphate pools and thymidine chemosensitization in human T cell leukemia. Leukemia Res. 17:1993;167-174.
18. Gandhi V., Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 48:1988;329-334.
19. Hunting D., Henderson J.F. Determination of deoxyribonucleoside triphosphates using DNA polymerase: a critical evaluation. Can. J. Biochem. 59:1981;723-727.
20. Olivares J., Verdys M. Isocratic high-performance liquid chromatographic method for studying the metabolism of blood plasma pyrimidine nucleosides and bases: concentration and radioactivity measurements. J. Chromatogr. 434:1988;111-121.
21. Eells J.T., Spector R. Determination of ribonucleosides, deoxyribonucleosides, and purine and pyrimidine bases in adult rabbit cerebrospinal fluid and plasma. Neurochem. Res. 8:1983;1307-1320.
22. Ross D.D., Thompson B.W., Joneckis C.C., Akman S.A., Schiffer C.A. Metabolism of araC by blast cells from patients with ANLL. Blood. 68:1986;76-82.
23. Bhalla K., Birkofer M., Arlin Z., Grant S., Safah H., Graham G. Differential effects of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells. Exp. Hematol. 19:1991;669-673.
24. Wiley J.S., Taupin J., Jamieson G.P., Snook M., Sawyer W.H., Finch L.R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J. Clin. Invest. 75:1985;632-642.
25. Noordhuis P., Kazemier K.M., Kasperrs G.J., Peters G.J. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leukemia Res. 20:1996;127-134.
26. Fox, R.M. (1989) Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. In: Inhibitors of Ribonucleoside Diphosphate Reductase Activity, pp. 113-126. Editors: J.G. Cory and A.H. Cory. Pergamon Press, New York.
27. Onetto N., Momparler R.L., Momparler L.F., Gyger M. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-aza-2′-deoxycytidine. Semin. Oncol. 14(Suppl. 2):1987;231-237.
28. Colly L.P., Peters W.G., Hermans J., Arentsen-Honders W., Willemze R. Percentage of S-phase cells in bone marrow aspirates, biopsy specimens and bone marrow aspirates corrected for blood dilution from patients with acute leukemia. Leukemia Res. 11:1987;209-213.
29. Spyrou G., Reichard P. Intracellular compartmentation of deoxycytidine nucleotide pools in S phase mouse 3T3 fibroblasts. J. Biol. Chem. 264:1989;960-964.
30. Spasokukotskaja T., Sasvari-Szekely M., Staub M. Compartmentation of dCTP pools disappears after hydroxyurea or araC treatment in lymphocytes. FEBS Lett. 297:1992;151-154.